Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA

Capricorn Fund Managers Ltd purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 300,000 shares of the company’s stock, valued at approximately $1,650,000. Capricorn Fund Managers Ltd owned 0.11% of Taysha Gene Therapies at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in TSHA. ST Germain D J Co. Inc. boosted its position in shares of Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in Taysha Gene Therapies during the third quarter worth about $40,000. Marex Group plc bought a new position in Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the second quarter valued at approximately $31,000. Finally, Allegheny Financial Group acquired a new stake in Taysha Gene Therapies during the third quarter valued at approximately $49,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $4.37 on Monday. The stock’s 50 day simple moving average is $4.54 and its 200 day simple moving average is $4.65. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $6.02. The firm has a market cap of $1.26 billion, a PE ratio of -12.85 and a beta of 1.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The business had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. As a group, sell-side analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Wall Street Zen upgraded Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Wells Fargo & Company boosted their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Finally, Needham & Company LLC upped their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Taysha Gene Therapies currently has a consensus rating of “Buy” and a consensus price target of $11.09.

Insider Activity at Taysha Gene Therapies

In related news, CFO Kamran Alam sold 78,968 shares of the company’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the transaction, the chief financial officer owned 1,467,635 shares in the company, valued at $6,971,266.25. This represents a 5.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sean P. Nolan sold 136,789 shares of the stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the sale, the chief executive officer directly owned 2,949,569 shares in the company, valued at approximately $14,010,452.75. This represents a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 598,623 shares of company stock valued at $2,822,188 over the last ninety days. 3.78% of the stock is owned by insiders.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.